Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
APOA1 encodes apolipoprotein A-I, which is the major protein component of high density lipoprotein (HDL) in plasma. Additionally we are shipping Apolipoprotein A-I Proteins (110) and Apolipoprotein A-I Kits (91) and many more products for this protein.
Showing 10 out of 526 products:
Human Monoclonal APOA1 Primary Antibody for EIA, WB - ABIN950461
Dastani, Dangoisse, Boucher, Desbiens, Krimbou, Dufour, Hegele, Pajukanta, Engert, Genest, Marcil: A novel nonsense apolipoprotein A-I mutation (apoA-I(E136X)) causes low HDL cholesterol in French Canadians. in Atherosclerosis 2006
Show all 2 references for ABIN950461
Mouse (Murine) Monoclonal APOA1 Primary Antibody for WB - ABIN968823
Cuthbert, Wang, Zhang, Tam: Regulation of human apolipoprotein A-I gene expression by gramoxone. in The Journal of biological chemistry 1997
Show all 2 references for ABIN968823
Human Monoclonal APOA1 Primary Antibody for EIA, RIA - ABIN111352
Jamil, Gordon, Eustice, Brooks, Dickson, Chen, Ricci, Chu, Harrity, Ciosek, Biller, Gregg, Wetterau: An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells. in Proceedings of the National Academy of Sciences of the United States of America 1996
Show all 2 references for ABIN111352
Human Monoclonal APOA1 Primary Antibody for ELISA, WB - ABIN1724693
Brown, Rea, Hamon, Hixson, Boerwinkle, Clark, Sing: The contribution of individual and pairwise combinations of SNPs in the APOA1 and APOC3 genes to interindividual HDL-C variability. in Journal of molecular medicine (Berlin, Germany) 2006
Show all 2 references for ABIN1724693
Human Polyclonal APOA1 Primary Antibody for IF (p), IHC (p) - ABIN728968
Liu, Zhao, Lu, Fan, Wang: Proteomic study on usnic-acid-induced hepatotoxicity in rats. in Journal of agricultural and food chemistry 2012
Show all 2 references for ABIN728968
Rat (Rattus) Monoclonal APOA1 Primary Antibody for WB - ABIN968824
Poncin, Martial, Gielen: Cloning and structure analysis of the rat apolipoprotein A-I cDNA. in European journal of biochemistry / FEBS 1984
Show all 2 references for ABIN968824
Human Polyclonal APOA1 Primary Antibody for EIA, IHC (fro) - ABIN116540
Bernthaler, Epping, Schmitz, Deplazes, Brehm: Molecular characterization of EmABP, an apolipoprotein A-I binding protein secreted by the Echinococcus multilocularis metacestode. in Infection and immunity 2009
Human Polyclonal APOA1 Primary Antibody for EIA, IHC (p) - ABIN359573
Simó, Higuera, García-Ramírez, Canals, García-Arumí, Hernández: Elevation of apolipoprotein A-I and apolipoprotein H levels in the vitreous fluid and overexpression in the retina of diabetic patients. in Archives of ophthalmology 2008
Chicken Polyclonal APOA1 Primary Antibody for EIA, WB - ABIN783514
Zhu, Wu, Zeng, Xue, Chen: Cysteine mutants of human apolipoprotein A-I: a study of secondary structural and functional properties. in Journal of lipid research 2005
Human Polyclonal APOA1 Primary Antibody for EIA, IF - ABIN499311
Sorci-Thomas, Prack, Dashti, Johnson, Rudel, Williams: Differential effects of dietary fat on the tissue-specific expression of the apolipoprotein A-I gene: relationship to plasma concentration of high density lipoproteins. in Journal of lipid research 1990
Compared with healthy controls, preeclamptic patients had significantly lower Apo A (show APOA Antibodies)-1 levels (167.07mg/dl+/-14.61mg/dl vs. 244.37mg/dl+/-20.84mg/dl, p<0.001), higher Apo B-100 (show APOB Antibodies)/Apo A (show APOA Antibodies)-1 ratio (0.63+/-0.07 vs. 0.42+/-0.05, p<0.001), but similar Apo B-100 (show APOB Antibodies) levels (104.84mg/dl+/-7.05mg/dl vs. 102.39mg/dl+/-8.08mg/dl, p=0.118).
ApoA-I induces S1P (show MBTPS1 Antibodies) release from endothelial cells through ABCA1 (show ABCA1 Antibodies) and SR-BI (show SCARB1 Antibodies) in a positive feedback manner.
ApoM (show APOM Antibodies)/HDL (show HSD11B1 Antibodies)-C and apoM (show APOM Antibodies)/apoA1 ratios could be used as indicators for identification of DN from healthy people and from T2DM patients.
AIBP (show APOA1BP Antibodies) promotes apoA-1 binding to ABCA1 (show ABCA1 Antibodies) on the cell membrane of macrophages and prevents ABCA1 (show ABCA1 Antibodies) protein from CSN2 (show CSN2 Antibodies)-mediated degradation so as to prevent foam cell formation
Higher level of some risk factors like PAB values, apoB (show APOB Antibodies)/A1 ratio concentration, and lipid profiles is able to involve in the prognostic pathological consequences in patients with beta-thalassemia major. Even so, they contribute toward the gradual development of CVD.
APOA1 SNPs (rs670, rs5069, and rs2070665) are not associated with dyslipidemia in the Kazakh population of China.
the data described the region around residue 217 in the C-terminal domain of apoA-I as the most sensitive reporter of the crowding-induced self-association of apoA-I. The implications of this behavior to in vivo functionality are discussed.
ApoA1 is increasingly expressed and secreted as a delayed response to neuronal injury, and this is a self-protecting mechanism of the injured system.
A novel APOA1 mutation in hereditary apolipoprotein A-I amyloidosis
The genotype frequency of APOA1 (rs5069, rs670) in a cohort of patients with CAA (show TSHZ1 Antibodies)-associated intracerebral hemorrhage was compared with hypertension-associated ICH (show COL4a2 Antibodies), Alzheimer disease, and controls. The APOA1 genotypes were not different among groups. apoA1 may act as a physiological transporter of Abeta (show APP Antibodies)(1-40).
results demonstrate that double deletion of Apoe (show APOE Antibodies) and Apoa1 ameliorated the amyloid pathology.
study suggests that apolipoprotein a1 can alleviate obesity related metabolic disease by inducing AMPK (show PRKAA1 Antibodies) dependent mitochondrial biogenesis.
ApoA-I can attenuate lymphocyte activation and autoimmunity in Lupus independently of cholesterol transport, through oxidized fatty acid peroxisome proliferator-activated receptor gamma (show PPARG Antibodies) ligands, and it can reduce renal inflammation in glomerulonephritis.
KLF14 (show SP6 Antibodies) regulates plasma HDL (show HSD11B1 Antibodies)-C levels and cholesterol efflux capacity by modulating hepatic ApoA-I production.
Akt (show AKT1 Antibodies), through its downstream targets, mTORC1 and hence autophagy, negatively regulates cholesterol efflux to apoA-I.
macrophage apoAI expression protects against atherosclerosis and dermatitis by reducing cholesterol accumulation and regulating CD4 (show CD4 Antibodies)(+) T-cell levels, without affecting serum HDL (show HSD11B1 Antibodies) or tissue macrophage levels.
HDL (show HSD11B1 Antibodies) from apoA1 transgenic mice expressing the 4WF isoform is resistant to oxidative loss of function.
ApoA1 levels were not associated with AngII-induced abdominal aortic aneurysms in mice.
decreased ApoAI synthesis might be accounted for the lower plasma HDL (show HSD11B1 Antibodies) level in ApoCIII (show APOC3 Antibodies) transgenic mice
MMP-8 (show MMP8 Antibodies)-deficient mice had significantly lower serum triglyceride (TG) levels (P = 0.003) and larger HDL (show HSD11B1 Antibodies) particles compared with wild-type (WT) mice. However, no differences were observed in the apoA-I levels.
Alterations in the Apo A (show APOA Antibodies)-I pattern is a good indicator of the presence and severity of infectious diseases in the pig.Lower overall amounts of Apo A (show APOA Antibodies)-I were observed in Salmonella typhimurium and Escherichia coli infections.
down-regulation of apolipoprotein A-I and A-IV messages in the liver may be mediated by interleukin 6 (show IL6 Antibodies) and tumor necrosis factor-alpha (show TNF Antibodies)
This study showed that apoA-I exerted protective effects against fatty liver disease in rabbits induced by a high-fat diet, possibly through its antioxidant actions.
The molar ratio ApoE (show APOE Antibodies)/ApoA-I is negatively correlated with the enzyme activity, and positively correlated with increases in the intima-media thickness of common carotid wall and cardiac dysfunction signs.
Binding of apoA-I to ectopic F(0)F(1) ATPase (show ATP5E Antibodies) triggers the generation of ADP, which via activation of the purinergic receptor P2Y (show P2RY1 Antibodies)(12) stimulates the uptake and transport of HDL (show HSD11B1 Antibodies) and initially lipid-free apoA-I by endothelial cells.
the model of a two-step process for the transendothelial transport of apoA-I in which apoA-I is initially lipidated by ABCA1 (show ABCA1 Antibodies) and then further processed by ABCA1 (show ABCA1 Antibodies)-independent mechanisms.
insulin (show INS Antibodies) secretion and tissue rejuvenation activities of WT-reconstituted high-density lipoproteins were nearly depleted by fructosylation, but V156K-rHDL did not lose its beneficial activity.
The NABB system using engineered zebrafish apo A-I is a native-like membrane mimetic system for G-protein-coupled receptors.
This gene encodes apolipoprotein A-I, which is the major protein component of high density lipoprotein (HDL) in plasma. The protein promotes cholesterol efflux from tissues to the liver for excretion, and it is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. This gene is closely linked with two other apolipoprotein genes on chromosome 11. Defects in this gene are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis.
, apolipoprotein A-I-like
, apolipoprotein A-I preproprotein
, apolipoprotein A1
, apolipoprotein A-1
, preproapolipoprotein A-I
, Apolipoprotein A1
, Apolipoprotein A-I